Daré Bioscience Shares Surge On Positive Phase 3 Data For Hormone-free Contraceptive Ovaprene
14/7 15:13
(RTTNews) - Shares of Daré Bioscience, Inc. (DARE) jumped more than 277.3400 per cent in the pre-market trading after the company announced positive interim safety and efficacy data for its ongoing Phase 3 trial of Ovaprene, a hormone-free, monthly intravaginal contraceptive....